Biogen BIIB Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Other | $223.2M+13.2% | $197.2M+25.5% | $157.1M+24.8% | $125.9M+30.2% | $96.7M+17.2% | |
| Total Revenue by Product | ||||||
| AVONEX | $691.9M-0.5% | $695.5M-1.1% | $703M+1.8% | $690.7M-0.7% | $695.8M-1.7% | |
| BENEPALI | $464M+2.4% | $453.2M-3.6% | $470.3M+0.8% | $466.5M-1.1% | $471.7M-1.5% | |
| BYOOVIZ | $23.5M-27.5% | $32.4M-4.1% | $33.8M-2.9% | $34.8M-12.8% | $39.9M+9.0% | |
| FAMPYRA | $1.1M-21.4% | $1.4M-90.5% | $14.7M-56.9% | $34.1M-35.4% | $52.8M-26.4% | |
| FLIXABI | $50M-4.9% | $52.6M-10.5% | $58.8M-1.5% | $59.7M+2.1% | $58.5M-7.4% | |
| FUMADERM And ADUHELM | $400K-81.0% | $2.1M-56.3% | $4.8M-30.4% | $6.9M-25.0% | $9.2M-10.7% | |
| IMRALDI | $192.4M+1.2% | $190.2M-3.8% | $197.7M-0.8% | $199.2M-3.2% | $205.7M-3.5% | |
| PLEGRIDY | $254.9M+1.9% | $250.1M-1.1% | $252.9M-1.1% | $255.8M+0.4% | $254.9M-2.1% | |
| QALSODY | $103.9M+19.6% | $86.9M+18.1% | $73.6M+26.2% | $58.3M+34.6% | $43.3M+33.6% | |
| SKYCLARYS | $547.3M+5.1% | $520.5M+6.4% | $489.3M+6.7% | $458.7M+7.1% | $428.4M+12.0% | |
| SPINRAZA | $1.5B-3.2% | $1.55B-4.0% | $1.61B-0.5% | $1.62B-2.2% | $1.66B+5.3% | |
| TECFIDERA | $583.1M-14.2% | $679.7M-14.6% | $795.7M-7.5% | $860.3M-6.4% | $918.9M-5.0% | |
| TOFIDENCE | $600K-14.3% | $700K+250% | $200K-50.0% | $400K-66.7% | $1.2M+9.1% | |
| TYSABRI | $1.73B+3.6% | $1.67B-1.1% | $1.68B+1.6% | $1.66B-0.5% | $1.67B-2.9% | |
| VUMERITY | $787M+5.4% | $746.8M+0.6% | $742.3M+8.2% | $685.8M+7.3% | $639.3M+1.8% | |
| ZURZUVAE | $222.8M+14.2% | $195.1M+28.1% | $152.3M+28.0% | $119M+36.0% | $87.5M+21.2% | |
| After Second GAZYVA Threshold Date by Product | ||||||
| GAZYVA | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | |
| RITUXAN | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | 140%0.0pp | |
| Share of non-controling interest recognized by Product | ||||||
| Alzheimer's collaboration revenue | 200%0.0pp | 200%0.0pp | 200%0.0pp | 200%0.0pp | 200%0.0pp | |
| Estimated additional payments upon achievement of development and commercial milestones by Product | ||||||
| Felzartamab And Izastobart/HIB210 | $2.56B0.0% | $2.56B— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Biogen break its business down?
- Biogen (BIIB) reports revenue by product across 2 parts — Contract manufacturing, royalty and other revenue and Other. Each is extracted from the segment footnotes and tracked over time.
- Where does Biogen's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Biogen's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
